Semaglutide in Europe: The 2026 Guide
7 min read · Updated September 2026
Semaglutide is the compound that made GLP-1 therapy a household topic across Europe, and interest continues to climb from Germany to the Netherlands and beyond. This guide explains what semaglutide is, how it is treated within European regulation, and how a protocol is approached: educational, specialist-led and matched on a consultation rather than self-selected.
What is semaglutide?
Semaglutide is a synthetic peptide that mimics GLP-1, a hormone released after eating that helps regulate appetite and blood sugar. It is a once-weekly injectable and the most studied member of the GLP-1 class. Its single-receptor mechanism is well understood, which is part of why clinicians often start here before considering the dual or triple agonists.
How semaglutide is regulated in Europe
In the European Union, semaglutide is a prescription-only medicine. It cannot be advertised directly to the public, and it is meant to be prescribed and monitored by a licensed clinician. That framework is why the sensible route in Europe is a consultation first: a specialist reviews your profile and confirms whether and how a protocol fits, rather than buying blind.
Semaglutide vs tirzepatide vs retatrutide
Read the class by receptor count: semaglutide targets GLP-1 alone, tirzepatide adds GIP as a dual agonist, and retatrutide adds glucagon as a triple agonist. Research effect broadly scaled with the added mechanisms, but the strongest compound on paper is not automatically the right one for you. Goals, history and tolerance decide, on a consultation.
How delivery and protocols work across the EU
Peptides are heat-sensitive, so look for lab-tested, pre-mixed and pre-dosed pens with a Certificate of Analysis, couriered cold-chain in insulated packaging with ice packs and refrigerated at 2 to 8C for storage. Titration and cycle length are set to your profile, and semaglutide supports metabolic goals alongside nutrition, training and sleep rather than replacing them.
Related peptides
Frequently asked
Is semaglutide legal in Europe?
Semaglutide is a prescription-only medicine across the European Union, prescribed and supervised by a licensed clinician. It cannot be advertised directly to the public, which is why an educational, consultation-led approach is the appropriate route.
How is semaglutide different from tirzepatide and retatrutide?
Semaglutide targets one receptor (GLP-1), tirzepatide targets two (GLP-1 and GIP), and retatrutide targets three (adding glucagon). Effects broadly scaled with mechanisms in research, but the right choice is matched to your profile on a consultation.
Do I need a prescription and consultation in the EU?
Yes. Semaglutide is prescription-only in Europe, so your suitability, dose and cycle are confirmed with a licensed clinician rather than self-prescribed.
How is semaglutide delivered across Europe?
In insulated, temperature-controlled packaging with ice packs, typically within one to three days, then refrigerated at 2 to 8C for storage.
For educational purposes only and not intended to diagnose, treat, cure or prevent any disease. Not a substitute for professional medical advice. Products are intended for adults 21+.